02:04:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Idag innehas verksamhet på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades under 2015 och har sitt huvudkontor i Oslo.

Kalender

2022-10-26 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-19 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning VISTN 0.50 NOK
2021-05-20 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-24 Extra Bolagsstämma 2020
2020-05-20 Ordinarie utdelning VISTN 1.00 NOK
2020-05-19 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning VISTN 0.00 NOK
2019-05-22 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-19 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning VISTN 1.00 NOK
2018-05-08 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-03 Bonusutdelning VISTN 7
2017-11-02 Extra Bolagsstämma 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning VISTN 1.00 NOK
2017-05-24 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-25 Ordinarie utdelning VISTN 0.60 NOK
2016-05-24 Årsstämma 2016
2016-04-28 Kvartalsrapport 2016-Q1
2016-02-23 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2021-10-28 07:45:00

Oslo, Norway, 28th of October 2021

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter 2021

Revenue in third quarter ended at MNOK 62.9 compared to MNOK 55.1 in Q3 2020. The revenue increase was driven by higher sales volume (+12%) and sales prices, offset by a significant stronger NOK vs EUR compared to last year.

Third quarter EBITDA ended at MNOK 4.6 (Q3’20: MNOK 9.5) a 52% decrease compared to similar quarter last year. The lower EBITDA in Q3’21 was driven by a stronger NOK vs EUR, increased raw material prices, record high international freight costs due to global constraints following Covid-19 and significantly higher electricity prices in the quarter compared to last year.

The net profit for the group ended at MNOK 1 (Q3’20: MNOK 4.5) for the third quarter of 2021.

Vistin Pharma had cash of MNOK 52 (Q3’20 MNOK: 98) as of 30 September 2021. Approx. 55% of the Metformin Expansion Project (MEP) has been paid as of end June. The company has a strong balance sheet with an equity ratio of 85% and no interest-bearing debt.

The Fikkjebakke plant is on track to achieve an all-time high production volume in 2021.

The third quarter conference call, which will be held today, 28th of October, at 8.30am (CET) and will be available via web and audio through the following access points:

Telephone conference:
Confirmation Code:             1860729
International dial-In:        +44 (0) 2071 928338
Norway, Oslo:                  +47 21563015
United States, New York:  +1 6467413167

Webcast:
https://edge.media-server.com/mmc/p/u59e5tiq

The conference call will be held in English.    

Please find the Q3 report and presentation enclosed. The report will also be made available on www.vistin.com.

 

*****

For further information, please contact:

Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby@vistin.com

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.